BNTX News and Press, BioNTech SE From 04/03/23

2023-04-03 18:44:09 ET In the next few weeks, the US FDA is likely to authorize a second booster shot specifically targeting COVID-19 Omicron variants for older individuals and those with weakened immune systems. The Washington Post reported that the goal is to provide those who...

2023-04-03 07:21:41 ET BioNTech ( NASDAQ: BNTX ) signed a licensning agreement with Duality Biologics (Suzhou) (DualityBio) for two antibody-drug conjugate (ADC) assets for solid tumors. Under the agreements, DualityBio will get $170M upfront for both asset licens...

BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers Collaboration will add a new class of precision medicine therapeutics to BioNTech’s...

2023-03-30 09:00:30 ET Moderna ( NASDAQ: MRNA ) signed an agreement with the government of the Republic of Kenya to set up an mRNA manufacturing facility in the African nation. This will be Moderna's first mRNA manufacturing facility in Africa. The facility, which w...

2023-03-28 13:41:06 ET Vaccine-developer Gritstone bio ( NASDAQ: GRTS ) trended higher on Tuesday after B. Riley launched its coverage with a Buy rating and a 12-month target of $8 per share, noting its prospects in messenger RNA technology. The analyst Mayank Mamtani argues...

2023-03-28 11:06:44 ET Summary BioNTech is quite undervalued after you back out its tremendous and growing cash hoard garnered from its COVID vaccine windfall. The company's mRNA technology and other therapies in development could support one of the cheapest long-term buy entries ...

2023-03-28 06:54:04 ET BioNTech SE ( NASDAQ: BNTX ) has approved to new buyback program to repurchase up to $0.5B of American Depositary Shares, each representing one ordinary share, of the company during the remainder of 2023. The drug maker expects to use all or a po...

MAINZ, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the Company may purchase American D...

2023-03-27 19:47:03 ET Summary BioNTech announced its Q422 and FY22 earnings today, and also provided FY23 guidance. Revenues were ~$18.7bn, thanks to its share of revenues from sales of the Comirnaty COVID vaccine it co-developed with Pfizer. Net profit was >$10bn. This ex...

2023-03-27 15:34:05 ET BioNTech SE (BNTX) Q4 2022 Results Conference Call March 27, 2023 08:00 AM ET Company Participants Michael Horowicz - IR and Strategy Ugur Sahin - CEO and Co-Founder Özlem Türeci - Chief Medical Officer and Co-Founder Jens Hol...